Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

StatusRecruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 6 months later Dec 1, 2026 → Jun 1, 2028
See other at-risk trials from SciTech Development, Inc.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Dec 1, 2026 to Jun 1, 2028
    • Study completion pushed from May 1, 2027 to Nov 1, 2028
    • Eligibility criteria expanded, about 36 words
    • Secondary endpoints: details revised at 4 of 4 entries
  2. Primary completion date: May 2025 to Dec 1, 2026
    • Study sites: 9 to 10
    • Study completion date: Nov 2025 to May 1, 2027
    v22
  3. Re-verified, no change to tracked fieldsv21
  4. Study sites: 8 to 9v20
  5. Study sites: 7 to 8v19
Show 17 earlier versionsHide 17 earlier versions
  1. Study sites: 6 to 7v18
  2. Secondary endpoints revised (4)v17
  3. Site contacts updated at 2 of 6 sitesv16
  4. Eligibility criteria expanded, about 30 wordsv15
  5. Study sites: 5 to 6v14
  6. Study sites: 4 to 5
    • Eligibility criteria expanded, about 132 words
    v13
  7. Start date changed from estimate of Dec 2023 to Dec 18, 2023v12
  8. Study sites: 3 to 4v11
  9. Trial status: Not Yet Recruiting to Recruitingv10 Show 4 more changesShow less
    • Primary completion date: Apr 2025 to May 2025
    • Study completion date: Oct 2025 to Nov 2025
    • Start date: Nov 2023 to Dec 2023
    • Site details revised at 3 of 3 sites
  10. Collaborators shortened, about 4 wordsv9
  11. Study sites: 2 to 3v8
  12. Study sites: 1 to 2v7
  13. Start date: Aug 2023 to Nov 2023
    • Primary completion date: Feb 2025 to Apr 2025
    • Study completion date: Aug 2025 to Oct 2025
    • Study site revised
    v6
  14. Primary completion date: Jun 2024 to Feb 2025
    • Start date: Dec 2022 to Aug 2023
    • Study completion date: Sep 2024 to Aug 2025
    v5
  15. Start date: Apr 2022 to Dec 2022
    • Primary completion date: Dec 2023 to Jun 2024
    • Study completion date: Jul 2024 to Sep 2024
    v4
  16. Primary completion date: Dec 2021 to Dec 2023
    • Start date: Jul 2020 to Apr 2022
    • Study completion date: Jul 2022 to Jul 2024
    v3
  17. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).
Trial Details
NCT Number NCT04234048
Lead Sponsor SciTech Development, Inc.
Conditions
(from sponsor)		 T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma, Peripheral T-Cell Lymphoma, Not Classified, Primary Cutaneous T-cell Lymphoma, Cutaneous T-Cell Lymphoma, Unspecified, Cutaneous T-cell Lymphoma, Follicular T-Cell Lymphoma +3 more
Related terms Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Mycosis Fungoides, Sezary Syndrome
Enrollment 46 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov